May lead to novel ways to diagnose, monitor brain
injury
Damaging tangles of the protein tau dot the brains
of people with neurodegenerative diseases like Alzheimer’s and boxer’s
dementia, and lead to memory loss, confusion and, in some, aggressive behavior.
But there is no easy way to determine whether people’s symptoms are linked to
tau tangles in their brains. Now, a team led by scientists at Washington
University School of Medicine in St. Louis has found a way to measure tau
levels in the blood. The method accurately reflects levels of tau in the brain
that are of interest to scientists because they correlate with neurological
damage. The study, in mice and a small group of people, could be the first step
towards a non-invasive test for tau.
Newswise, May 20, 2017 — Damaging tangles of the protein tau
dot the brains of people with Alzheimer’s and many other neurodegenerative
diseases, including chronic traumatic encephalopathy, which plagues
professional boxers and football players.
Such tau-based diseases can lead to memory loss, confusion
and, in some, aggressive behavior. But there is no easy way to determine
whether people’s symptoms are linked to tau tangles in their brains.
Now, however, a team led by scientists at Washington
University School of Medicine in St. Louis has found a way to measure tau
levels in the blood. The method accurately reflects levels of tau in the brain
that are of interest to scientists because they correlate with neurological
damage.
The study, in mice and a small group of people, could be the
first step toward a noninvasive test for tau.
While further evaluation in people is necessary, such a test
potentially could be used to quickly screen for tau-based diseases, monitor
disease progression and measure the effectiveness of treatments designed to
target tau.
The research is published April 19 in Science
Translational Medicine.
“We showed that you can measure tau in the blood, and it
provides insight into the status of tau in the fluid surrounding cells in
brain,” said senior author David Holtzman, MD, the Andrew B. and Gretchen P. Jones
Professor and head of the Department of Neurology at Washington University
School of Medicine in St. Louis.
Tau is a normal brain protein involved in maintaining the
structure of neurons. But when tau forms tangles, it damages and kills nearby
neurons.
“People with tau diseases have a wide range of symptoms
because basically, wherever tau is aggregating, those parts of the brain are
degenerating,” Holtzman said. “So if it’s in a memory area, you get memory
problems. If it’s in a motor area, you get problems with movement.”
A blood-based screening test, likely years away, would be a
relatively easy way to identify people whose symptoms may be due to problems
with tau, without subjecting them to potentially invasive, expensive or
complicated tests.
“We have no test that accurately reflects the status of tau in
the brain that is quick and easy for patients,” Holtzman said. “There are brain
scans to measure tau tangles, but they are not approved for use with patients
yet.
Tau levels can be measured in the cerebrospinal fluid that
surrounds the brain and spinal cord, but in order to get to that fluid, you
have to do a spinal tap, which is invasive.”
In the brain, most tau proteins are inside cells, some are in
tangles, and the remainder float in the fluid between cells. Such fluid
constantly is being washed out of the brain into the blood, and tau comes with
it. However, the protein is cleared from the blood almost as soon as it gets
there, so the levels, while detectable, typically remain very low.
Holtzman, postdoctoral researcher Kiran Yanamandra, PhD, and
MD/PhD student Tirth Patel, along with colleagues from C2N
Diagnostics, AbbVie, the University of California, San Francisco, and Texas
Health Presbyterian Hospital, reasoned that if they could keep tau in the blood
longer, the protein would accumulate to measurable levels.
Allowing the protein to
accumulate before measuring its levels would magnify – but not distort –
differences between individuals, in the same way that enlarging a picture of a
grain of sand alongside a grain of rice does not change the relative size of
the two, but does make it easier to measure the difference between them.
The researchers injected a known amount of tau protein
directly into the veins of mice and monitored how quickly the protein
disappeared from the blood. The researchers showed that half the protein
normally disappears in less than nine minutes.
When they added an antibody that binds to tau, the half-life
of tau was extended to 24 hours. The antibody was developed in the laboratories
of Holtzman and Marc Diamond, MD, of the University of Texas Southwestern
Medical Center, and is currently licensed to C2N Diagnostics, which is
collaborating with the pharmaceutical company AbbVie in developing the
technology.
To determine whether the antibody could amplify tau levels in
an animal’s blood high enough to be measured easily, they injected the antibody
into mice.
Within two days, tau levels in the mice’s blood went up into
the easily detectable range. The antibody acted like a magnifying glass,
amplifying tau levels so that differences between individuals could be seen
more easily.
Tau levels in people’s blood also rose dramatically in the
presence of the antibody. The researchers administered the antibody to four people
with a tau disease known as progressive supranuclear palsy. Their blood levels
of tau rose 50- to 100-fold within 48 hours.
“It’s like a stress test,” Holtzman said. “We appear to be
bringing out the ability to see what’s coming from the brain because the
antibody amplifies differences by prolonging the time the protein stays in the
blood.”
Measuring tau levels in the blood is only useful if it
reflects tau levels in the brain, where the protein does its damage, the
researchers said.
Both high and low levels of tau in the fluid that surrounds
the brain could be a danger sign. Alzheimer’s and chronic traumatic
encephalopathy both are associated with high levels of soluble tau, whereas
progressive supranuclear palsy and other genetic tau diseases are thought to be
associated with low levels.
To see whether elevated brain tau is reflected in the blood,
the researchers treated mice with a chemical that injures neurons. The chemical
causes tau to be released from the dying neurons, thereby raising tau levels in
the fluid surrounding the cells. The scientists saw a corresponding increase of
tau in the blood in the presence of the anti-tau antibody.
To lower tau levels, the researchers turned to genetically
modified mice that, as they age, have less and less tau floating in their
cerebrospinal fluid.
Such mice at 9 months old had significantly lower tau levels
in their blood than 3-month-old mice with the same genetic modification, again
demonstrating the antibody’s ability to reflect levels of tau in the brain.
“It will be helpful in future studies to see if the
measurement of tau in the blood following antibody treatment in humans reflects
the state of tau in the brain,” Holtzman said.